• Company
• Rozlytrek can be prescribed at Big 5 hospitals
• by Eo, Yun-Ho Dec 6, 2022 05:57am

• Policy
• "A9 countries not used for drug pricing reevals next year"
• by Kim, Jung-Ju Dec 5, 2022 05:53am

• Policy
• Implementation of projects linked to permission evaluation
• by Kim, Jung-Ju Dec 5, 2022 05:53am

• Policy
• MOHW “reasonably decide on using A9 countries as reference"
• by Kim, Jung-Ju Dec 5, 2022 05:53am

• Policy
• The safety & efficacy evaluation of Jemperili was terminated
• by Lee, Hye-Kyung Dec 5, 2022 05:53am

• Policy
• Domestic new drug No. 36 Envlo has been approved
• by Lee, Hye-Kyung Dec 5, 2022 05:53am

• InterView
• The issue of SE of JAK inhibitors should be given authority
• by Kim, Jin-Gu Dec 2, 2022 06:08am

• Company
• Leclaza P3T results unveiled... mPFS 20 months
• by Dec 2, 2022 06:07am

• Company
• Competition for chronic kidney disease following SGLT-2 I
• by Eo, Yun-Ho Dec 2, 2022 06:07am

• Company
• Balversa, the first targeted anticancer drug for bladder can
• by Dec 2, 2022 06:07am